ArticleDaru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences2026
Cost-Effectiveness of olaparib plus bevacizumab versus bevacizumab monotherapy as first-line maintenance for patients with advanced ovarian cancer: a analysis from a Chinese healthcare perspective.
Pengxiang Cai et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.